<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137979">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049281</url>
  </required_header>
  <id_info>
    <org_study_id>8109-011</org_study_id>
    <secondary_id>142501</secondary_id>
    <nct_id>NCT02049281</nct_id>
  </id_info>
  <brief_title>A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)</brief_title>
  <official_title>A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate thrice weekly dosing with vintafolide to find the maximum tolerable
      dose. The primary study hypothesis is that administration of vintafolide to participants
      with advanced solid tumors will have acceptable safety and tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants Experiencing Dose-limiting Toxicities</measure>
    <time_frame>Up to 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Vintafolide</measure>
    <time_frame>Cycle 1, Day1 predose and at 2, 5, 10, 20, 30, 45, 60, 90 and 120 minutes post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) for Vintafolide</measure>
    <time_frame>Cycle 1, Day1 predose and at 2, 5, 10, 20, 30, 45, 60, 90 and 120 minutes post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of desacetylvinblastine hydrazide (DAVLBH)</measure>
    <time_frame>Cycle 1, Day1 predose and at 2, 5, 10, 20, 30, 45, 60, 90 and 120 minutes post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Vintafolide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive vintafolide intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vintafolide</intervention_name>
    <arm_group_label>Vintafolide</arm_group_label>
    <other_name>MK-8109</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed metastatic or locally advanced solid tumor that has failed
             to respond to standard therapy, progressed despite standard therapy, or for which
             standard therapy does not exist

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate organ function

        Exclusion Criteria:

          -  Chemotherapy, radiotherapy, or biological therapy (including monoclonal antibodies)
             within 4 weeks prior to drug administration (6 weeks for nitrosoureas or mitomycin C)
             or not recovered from adverse events due to agents administered more than 4 weeks
             earlier

          -  Primary central nervous system (CNS) tumor

          -  Active CNS metastases and/or carcinomatous meningitis

          -  Known hypersensitivity to the components of the study therapy or its analogs

          -  Recent history of abdominal surgery or peritonitis

          -  Bowel occlusion or sub occlusion

          -  Prior abdominal or pelvis radiation therapy or radiation therapy to &gt; 10% of the bone
             marrow at any time in the past or prior radiation therapy within the last three years
             to the breast / sternum, head, or neck

          -  Requires anti-folate therapy

          -  Symptomatic ascites or pleural effusion

          -  Prior stem cell or bone marrow transplant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>MSD K.K.</name>
      <address>
        <city>Chiyoda-Ku, Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Japan Call Center</last_name>
      <phone>81-3-6272-1957</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vinca Alkaloids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
